A research team at Flinders University in Australia developed the vaccine using adjuvants, which are substances that enhance the immune response, according to Dr. Nikolai Petrovsky, professor and research director of Vaxine Pty Ltd. at Flinders. It is believed to be the first human drug entirely designed by artificial intelligence.
This year’s flu vaccine became less effective later in the season, when a second wave of the disease emerged with a tougher flu strain. The vaccine was only 29 percent effective overall. The new drug will be tested in the U.S. for about 12 months and will involve 240 healthy volunteers.
More articles on clinical leadership and infection control:
Push to reduce low-value care often neglects patient experience, study finds
San Francisco hospital CEO resigns amid patient abuse scandal
Flu shot was 29% effective this season, CDC says
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
